Plerixafor and pegylated filgrastim: a case of safe and effective hematopoietic stem cell mobilization

@article{Fesler2010PlerixaforAP,
  title={Plerixafor and pegylated filgrastim: a case of safe and effective hematopoietic stem cell mobilization},
  author={Mark J. Fesler and Ganesh C. Kudva and Paul J. Petruska},
  journal={Bone Marrow Transplantation},
  year={2010},
  volume={45},
  pages={1367-1368}
}
Plerixafor, a Food and Drug Administration-approved CXCR4 antagonist for hematopoietic stem cell mobilization, is effective at mobilizing hematopoietic stem cells in patients with non-Hodgkin’s lymphoma when administered with G-CSF. Most centers initiate peripheral blood hematopoietic stem cell apheresis early in the week, as some patients require 4 to 5 days to achieve satisfactory stem cell yields. The regimen of filgrastim and plerixafor requires filgrastim administration daily, starting 4… CONTINUE READING
0 Extracted Citations
2 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.
Showing 1-2 of 2 references

Feasibility of Cd34-positive stem cell mobilization by administration of AMD3100 six hours prior to leukapheresis

  • A Chari, A Vendivil, S Clark-Garvey, J Schwartz, R Slotky, D Diuguid
  • Biol Blood Marrow Transplant
  • 2009

Similar Papers

Loading similar papers…